<DOC>
	<DOCNO>NCT00563316</DOCNO>
	<brief_summary>The primary objective study determine panitumumab affect pharmacokinetic ( PK ) profile irinotecan .</brief_summary>
	<brief_title>Effect Panitumumab Pharmacokinetics Irinotecan</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Pathologically confirm unresectable metastatic colorectal cancer ( mCRC ) progress least one prior 5fluorouracil ( 5FU ) contain chemotherapy regimen Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 , 2 Life expectancy ≥ 3 month document investigator Baseline actual body weight ≤ 160 kg Competent comprehend , sign , date write Institutional Review Board ( IRB ) approve informed consent form studyspecific procedure perform Treatment radiotherapy ≤ 14 day enrollment . Patients must recover radiotherapyrelated toxicity Known presence central nervous system ( CNS ) metastases Any prior malignancy ( except nonmelanomatous skin cancer situ cervical cancer ) study disease , unless treat curative intent evidence disease ≤ 2 year enrollment History interstitial lung disease ( eg , pneumonitis pulmonary fibrosis ) evidence interstitial lung disease baseline chest compute tomography ( CT ) scan Active inflammatory bowel disease bowel disease cause chronic diarrhea ( defined &gt; Common Terminology Criteria Adverse Events ( CTCAE version 3 ) grade 2 Clinically significant cardiovascular disease ( include myocardial infarction , unstable angina , symptomatic congestive heart failure , serious uncontrolled cardiac arrhythmia ) ≤ 1 year enrollment UGT1A1*28 TA7/7 , TA7/8 , TA8/8 genetic polymorphism ; Gilbert 's Disease Treatment CYP3A4 enzyme inhibit induce medication ≤ 2 week enrollment Prior antiepidermal growth factor receptor ( EGFr ) antibody therapy ( eg , cetuximab ) treatment small molecule EGFr inhibitor ( eg , gefitinib , erlotinib , lapatinib ) Systemic chemotherapy , hormonal therapy , immunotherapy , experimental approve proteins/antibodies ( eg , bevacizumab ) ≤ 30 day enrollment Subjects require immunosuppressive agent ( eg , methotrexate cyclosporine ) , however corticosteroid allow Major surgery &lt; 28 day prior enrollment minor surgery ( exclude catheter placement ) &lt; 14 day enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>colorectal cancer</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>cancer</keyword>
	<keyword>metastatic</keyword>
	<keyword>irinotecan</keyword>
	<keyword>EGFr</keyword>
	<keyword>epidermal growth factor</keyword>
</DOC>